Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2026-01-01 @ 11:08 AM
Study NCT ID:
NCT02598635
Status:
UNKNOWN
Last Update Posted:
2017-03-24
First Post:
2015-10-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2019-01-11', 'releaseDate': '2018-07-15'}], 'estimatedResultsFirstSubmitDate': '2018-07-15'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D014808', 'term': 'Vitamin D Deficiency'}, {'id': 'D061205', 'term': 'Vascular Calcification'}, {'id': 'D051437', 'term': 'Renal Insufficiency'}], 'ancestors': [{'id': 'D001361', 'term': 'Avitaminosis'}, {'id': 'D003677', 'term': 'Deficiency Diseases'}, {'id': 'D044342', 'term': 'Malnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D002114', 'term': 'Calcinosis'}, {'id': 'D002128', 'term': 'Calcium Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D002762', 'term': 'Cholecalciferol'}], 'ancestors': [{'id': 'D002782', 'term': 'Cholestenes'}, {'id': 'D002776', 'term': 'Cholestanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D013261', 'term': 'Sterols'}, {'id': 'D014807', 'term': 'Vitamin D'}, {'id': 'D012632', 'term': 'Secosteroids'}, {'id': 'D008563', 'term': 'Membrane Lipids'}, {'id': 'D008055', 'term': 'Lipids'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 58}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2015-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-03', 'completionDateStruct': {'date': '2017-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-03-22', 'studyFirstSubmitDate': '2015-10-31', 'studyFirstSubmitQcDate': '2015-11-05', 'lastUpdatePostDateStruct': {'date': '2017-03-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2015-11-06', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Relative reduction in serum osteoprotegerin (OPG) levels assessed by ELISA (in pg/mL) between study inclusion, and the 16-week intervention period.', 'timeFrame': '16 weeks', 'description': 'The concentrations of OPG will be assessed using ELISA (Austin, Texas, USA) at inclusion and after 16 weeks of treatment with cholecalciferol or placebo.Minimum detectable concentrations for OPG are 1.9 pg/mL; intra and inter-assay coefficients of variability are 5% and 11% for OPG.'}], 'secondaryOutcomes': [{'measure': 'Relative reduction in circulating intact fibroblast growth factor 23 (FGF23) levels (in pg/mL)', 'timeFrame': '16 weeks', 'description': 'The concentrations of intact FGF-23 will be assessed using ELISA (Austin, Texas, USA)'}, {'measure': 'Relative reduction in circulating osteopontin (OPN) levels (in pg/mL)', 'timeFrame': '16 weeks', 'description': 'The concentrations of OPN will be assessed using ELISA (Austin, Texas, USA)'}, {'measure': 'Relative reduction in circulating osteocalcin (OCN) levels (in pg/mL)', 'timeFrame': '16 weeks', 'description': 'The concentrations of OCN will be assessed using ELISA ( Austin, Texas, USA)'}, {'measure': 'Relative reduction in intima-media thickness measurements in the carotid artery. Ultrasound examination will be performed at study inclusion, at 16 weeks after inclusion, and up to 52 weeks post inclusion.', 'timeFrame': '52 weeks', 'description': "Ultrasound examination will be performed with the use of an 8-megahertz annular array ultrasound imaging system by a single trained sonographer. With this technique, 2 parallel echogenic lines separated by an anechoic space can be visualized at levels of the artery wall. The distance between the 2 lines gives a reliable index of the thickness of the intimal-medial complex. Subjects will be examined in the supine position. Ultrasound scans of the right and left last distal centimeter of common carotid arteries and bifurcation and of the first proximal centimeter of internal carotid arteries in 3 different projections (anterior, lateral, and posterior) will be performed. All measurements will be made at the time of scanning on unfrozen images of longitudinal scans by using the machine's electronic caliper."}, {'measure': 'Number of participants with courses of corrected calcium (>10.5 mg/dL) and phosphorus (>7 mg/dL) levels', 'timeFrame': '16 weeks', 'description': 'During follow-up, all participants will be interviewed. All participants will be interviewed and a blood sample will be taken every 4-6 weeks.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Cholecalciferol', 'peritoneal dialysis', 'FGF23', 'Calcium', 'Phosphorus'], 'conditions': ['Vitamin D Deficiency', 'Vascular Calcification', 'Renal Insufficiency', 'End Stage Renal Failure on Dialysis']}, 'referencesModule': {'references': [{'pmid': '26293840', 'type': 'RESULT', 'citation': 'Ramirez-Sandoval JC, Casanova I, Villar A, Gomez FE, Cruz C, Correa-Rotter R. Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis. Perit Dial Int. 2016 May-Jun;36(3):262-8. doi: 10.3747/pdi.2014.00250. Epub 2015 Aug 20.'}, {'pmid': '17468488', 'type': 'RESULT', 'citation': 'Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Santos RD, Miname M, Canziani ME. The progression and impact of vascular calcification in peritoneal dialysis patients. Perit Dial Int. 2007 May-Jun;27(3):340-6.'}, {'pmid': '25770176', 'type': 'RESULT', 'citation': 'Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, Ankers E, Wenger J, Tucker JK, Trottier C, Pathan F, Kalim S, Nigwekar SU, Thadhani R. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol. 2015 Apr 7;10(4):611-9. doi: 10.2215/CJN.06910714. Epub 2015 Mar 13.'}, {'pmid': '19007931', 'type': 'RESULT', 'citation': 'Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. 2009 Jun;204(2):321-9. doi: 10.1016/j.atherosclerosis.2008.09.033. Epub 2008 Oct 9.'}, {'pmid': '23535831', 'type': 'RESULT', 'citation': 'Janda K, Krzanowski M, Chowaniec E, Kusnierz-Cabala B, Dumnicka P, Krasniak A, Podolec P, Sulowicz W. Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. Pol Arch Med Wewn. 2013;123(4):149-55. doi: 10.20452/pamw.1678. Epub 2013 Mar 26.'}]}, 'descriptionModule': {'briefSummary': 'Aim: To investigate whether cholecalciferol (4800 U/daily) or placebo for 16 weeks reduces proteins levels associated with vascular calcification (osteoprotegerin, osteopontin, osteocalcin) in patients treated with peritoneal dialysis and 25(OH) vitamin D deficiency.', 'detailedDescription': 'Patients with chronic kidney disease on peritoneal dialysis have very low 25-(OH) vitamin D levels. Vitamin D deficiency may be involved in generalized atherosclerosis, vascular calcification and cardiovascular mortality. Among others, Osteoprotegerin (OPG) has been implicated in the pathogenesis leading up vessel calcification in this patients. Furthermore, very low levels of 25-(OH) vitamin D in peritoneal dialysis patients are associated with increased levels of OPG and high values of vascular calcification scores in x-rays.\n\nIt is unknown whether cholecalciferol supplementation in patients on peritoneal dialysis with low levels of 25-(OH) vitamin D could change the proteins associated with vascular calcification.\n\nThe objective is to conduct a randomized, double-blind, placebo-controlled study focusing on the impact of Cholecalciferol substitution in 25-OH vitamin D deficient peritoneal dialysis patients on circulating OPG and other osteogenic biomarkers levels during 16 weeks of intervention.\n\nMoreover, the impact of cholecalciferol on serum calcium and phosphorus levels, Kidney Disease Quality of Life Short Form, and ultrasound characteristics of carotid arterial will be performed during the first four weeks after inclusion, and after 28 weeks postintervention.\n\nPeritoneal dialysis patients found to have 25-(OH) vitamin D levels \\<20 ng/ml will be included and will be randomized to receive either oral cholecalciferol therapy or placebo. Cholecalciferol will be administered at a daily dose of 4800 IU over a time period of 16 weeks.\n\nAll in all, 58 subjects will be included in this study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '100 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Peritoneal dialysis treatment for at least 3 months.\n* Concentrations of 25-oh vitamin D \\<20 ng / mL\n* Corrected calcium \\<10.5 mg / dL\n* Serum phosphorus \\<7.0 mg / dL\n* Intact parathyroid hormone \\> 50 pg / mL and \\<1500 pg/mL\n\nExclusion Criteria:\n\n* Active participation in another protocol.\n* Vitamin D deficiency due to a hereditary disease or liver disease.\n* Use of cholecalciferol ≥ 2000 IU per day within 6 months prior\n* New prescription of calcitriol or paricalcitol at any dose within three months prior to the intervention (The subjects may be taking calcitriol or paricalcitol only if these drugs are taken at least three months before and no substantial changes in dosage have been made).\n* Use of bisphosphonates.\n* Treatment with anticonvulsants or other drugs that affect the metabolism of vitamin D.\n* Pregnancy and lactation.\n* Active cancer or other active inflammatory disease.\n* HIV or AIDS'}, 'identificationModule': {'nctId': 'NCT02598635', 'briefTitle': 'Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis', 'organization': {'class': 'OTHER', 'fullName': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran'}, 'officialTitle': 'Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial', 'orgStudyIdInfo': {'id': '1419'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cholecalciferol', 'description': 'A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels \\> 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels \\> 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to \\< 10.6 mg/dL and/or \\<7.1 mg/dL respectively.', 'interventionNames': ['Drug: Cholecalciferol']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels \\> 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels \\> 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to \\< 10.6 mg/dL and/or \\<7.1 mg/dL respectively.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Cholecalciferol', 'type': 'DRUG', 'otherNames': ['"Valmetrol-3"'], 'description': 'Patients on peritoneal dialysis and 25-(OH) levels \\<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.', 'armGroupLabels': ['Cholecalciferol']}, {'name': 'Placebo', 'type': 'DRUG', 'otherNames': ['(Capsule similar to Cholecalciferol)'], 'description': 'An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '01400', 'city': 'Mexico City', 'state': 'Mexico City', 'country': 'Mexico', 'facility': 'National Medical Science and Nutrition Institute Salvador Zubiran MEXICO', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}], 'overallOfficials': [{'name': 'Ricardo Correa-Rotter, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Head Dept Nephrology and Mineral Metabolism National Medical Science and Nutrition Institute Salvador Zubiran MEXICO'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'MD', 'investigatorFullName': 'Juan C Ramirez-Sandoval', 'investigatorAffiliation': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran'}}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedEvents': [{'date': '2018-07-15', 'type': 'RELEASE'}, {'date': '2019-01-11', 'type': 'RESET'}], 'unpostedResponsibleParty': 'Juan C Ramirez-Sandoval, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran'}}}}